Strategic expansion IBA is actively expanding its proton therapy footprint globally, including a first proton therapy center in Rio de Janeiro, Brazil. This signals growing demand for installed systems and ongoing service contracts in new markets, presenting opportunities for equipment provisioning, installation, commissioning, and after-sales support.

Hospital & pharma ties The company supplies radiopharmaceutical production solutions and cyclotron technologies (eg Cyclone KIUBE) for U.S. radiopharmacies and clinical manufacturing. This creates cross-sell potential into hospital networks, cancer centers, and contract manufacturing organizations that require reliable particle accelerator and radiopharmacy capabilities.

Leadership growth IBA recently strengthened its leadership and board with strategic appointments, signaling a growth phase and focus on corporate ventures. This aligns with potential partnerships, joint ventures, or channel partnerships to accelerate market reach and product adoption.

Financial health With substantial revenue scale and a recent dividend event, IBA demonstrates financial stability and investor confidence, enabling us to position premium solution offerings, long-term service agreements, and financing options to health systems and research institutions.

Sustainability edge As a certified B Corporation with a focus on social and environmental performance, IBA can leverage its sustainability credentials to win bids that emphasize ESG criteria, potentially differentiating from competitors in procurement processes for hospitals and government-funded programs.